Leaflet: information for the user
Emconcor 5 mg film-coated tablets
Bisoprolol fumarate
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
The active ingredient in Emconcor is bisoprolol. Bisoprolol belongs to a group of medications called beta-blockers. These medications act by affecting the body's response to certain nerve impulses, particularly in the heart. As a result, bisoprolol slows the heart rate and makes the heart more efficient, pumping blood throughout the body. At the same time, it reduces the heart's need for blood and oxygen.
Emconcor is used to treat high blood pressure (elevated blood pressure) and chronic stable angina.
Do not take Emconcor
Do not take Emconcor if you have any of the following conditions:
Do not take Emconcor if you have any of the following heart problems:
Warnings and precautions
If you have any of the following, inform your doctor before taking Emconcor:
Also, inform your doctor if you are going to:
Children and adolescents
Emconcor is not recommended for use in children or adolescents.
Use of Emconcor with other medications
Inform your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medication.
Do not take the following medications with Emconcor without special advice from your doctor:
Consult your doctor before taking the following medications with Emconcor; your doctor may need to monitor your condition more frequently:
Pregnancy and breastfeeding
There is a risk that the use of Emconcor during pregnancy may harm the baby.
If you are pregnant or planning to become pregnant, inform your doctor. Your doctor will decide if you can take Emconcor during pregnancy.
The passage of Emconcor into human breast milk is unknown. Breastfeeding is not recommended during treatment with Emconcor.
Driving and operating machinery
Your ability to drive or operate machinery may be affected depending on how you tolerate the medication. Be especially careful at the start of treatment and with changes in dosage or medication, and also in combination with alcohol.
Important information about some of the components of Emconcor
It is reported to athletes that this medication contains a component that may result in a positive analytical result for doping control.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The treatment with Emconcor should be initiated gradually with low doses, which should be increased gradually. In all cases, the dose should be adjusted individually, particularly according to heart rate and therapeutic success.
Dosage
For both indications, the normal dose is one Emconcor 5 mg tablet or half of an Emconcor 10 mg tablet (equivalent to 5 mg of bisoprolol) once a day.
If necessary, the dose can be increased to one Emconcor 10 mg tablet or two Emconcor 5 mg tablets (equivalent to 10 mg of bisoprolol) once a day.
The maximum recommended dose is 20 mg once a day.
Treatment duration
The treatment with Emconcor is normally long-term.
Dosage in case of liver or kidney insufficiency
In patients with mild to moderate liver or kidney dysfunction, no dose adjustment is usually required. In patients with severe renal insufficiency (creatinine clearance <20
Dosage in the elderly
No dose adjustment is required in the elderly.
Method of administration
Take the tablet with a little water in the morning, with or without food. Do not crush or chew the tablet.
If you take more Emconcor than you should
If you have taken more Emconcor than you should, inform your doctor immediately. Your doctor will decide what actions are necessary.
The symptoms of an overdose include decreased heart rate (bradycardia), difficulty breathing (bronchospasm), sudden drop in blood pressure, acute heart failure, or decreased blood sugar levels.
In case of overdose or accidental ingestion, consult the Toxicological Information Service: Tel. 91.562.04.20.
If you forget to take Emconcor
Do not take a double dose to compensate for the missed doses. Take the usual dose the next morning.
If you interrupt the treatment with Emconcor
Never stop taking Emconcor except on the advice of your doctor. Otherwise, your condition may worsen significantly. The treatment should not be interrupted abruptly, especially in patients with ischemic heart disease. If you need to interrupt the treatment, your doctor will instruct you on how to gradually reduce the dose.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, Emconcor may cause side effects, although not everyone will experience them.
The following side effects are listed in order of their possible frequency of occurrence:
Frequent(may affect up to 1 in 10 people):
Infrequent(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1000 people):
Very rare(may affect up to 1 in 10,000 people):
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this prospectus.
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: www.notificaRAM.es.
By reporting side effects, you can contribute to providing more information on the safety of this medication.
No special conservation conditions are required.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medications. By doing so, you will help protect the environment.
Tablet core:anhydrous colloidal silica, magnesium stearate, crospovidone, microcrystalline cellulose, cornstarch, anhydrous calcium hydrogen phosphate.
Covering:titanium dioxide (E 171), macrogol 400, dimethicone, yellow iron oxide (E 172), hypromellose.
Appearance of the product and contents of the packaging
Emconcor 5: pale yellow, scored on both sides, and cylindrical tablets.
Packaging of 60 tablets.
Holder of the marketing authorization and responsible for manufacturing:
Holder of the Marketing Authorization:
Merck, S.L.
María de Molina, 40
28006, Madrid
Spain
Responsible for manufacturing
Merck Healthcare KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
or
Merck, S.L.
Merck Industrial Estate, 08100
Mollet del Vallés (Barcelona)
Spain
Last review date of this leaflet: 11/2020
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.